Pharmacoeconomic analysis of treatment of patients infected with hepatitis C virus

Hepatitis C infection imposes a high economic burden globally. It has been estimated that in 2012, the healthcare cost of Hepatitis C virus (HCV) was $6.5 billion. Furthermore, it has been projected that the cost will reach at $9.1 billion by the year 2024.Frequency of hepatitis C in Pakistan is sig...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pakistan journal of pharmaceutical sciences 2018-03, Vol.31 (2), p.365-369
Hauptverfasser:	Qureshi, Sadia, Qazi, M H, Aziz, Muhammad Tahir
Format:	Artikel
Sprache:	eng
Schlagworte:	Analysis Antiviral Agents - economics Antiviral Agents - therapeutic use Care and treatment Cohort Studies Drug Costs Drug Therapy, Combination - economics Economics, Pharmaceutical Female Hepatitis C Hepatitis C - drug therapy Hepatitis C - economics Humans Interferon alpha-2 - economics Interferon alpha-2 - therapeutic use Interferon-alpha - economics Interferon-alpha - therapeutic use Male Medical care, Cost of Pakistan Polyethylene Glycols - economics Polyethylene Glycols - therapeutic use Prospective Studies Recombinant Proteins - economics Recombinant Proteins - therapeutic use Ribavirin - economics Ribavirin - therapeutic use Sustained Virologic Response Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!